Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients

Prostate

Volumn 33, Issue 4, 1997, Pages 281-285

  Murphy, Gerald P ^a   Maguire, Robert T ^b   Rogers, Barbara ^c   Partin, Alan W ^d   Nelp, Wil B ^e   Troychak, Michael J ^a   Ragde, Haakon ^a   Kenny, Gerald M ^a   Barren III, Robert J ^a   Bowes, Victoria A ^a   Gregorakis, A K ^a,f   Holmes, Eric H ^a   Boynton, Alton L ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Targon Corporation   (United States)

^c Cytogen Corporation   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Antigen; Pathologic stage; ProstaScint scan; Prostate cancer; Prostate specific antigen; Prostate specific membrane; PSA; PSMA

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER STAGING; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE DISEASE;

ADULT; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BLOTTING, WESTERN; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING;

EID: 0030734572     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971201)33:4<281::AID-PROS9>3.0.CO;2-K     Document Type: Article

References (25)

1. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-936.
2. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-241.
3. Murphy GP: Radioscintiscanning of prostate cancer. Cancer 1995;75:1819-1822.
4. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Erickson SJ, Kenny GM, Murphy GP: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-223.
5. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ: A comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP based ELISA assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 1995;26:164-168.
6. Murphy G, Ragde H, Kenny G, Barren R III, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15: 1473-1480.
7. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV: Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site specific immunoconjugates. Cancer [Suppl] 1993;72:3453-3462.
8. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV: Radioimmunoscintigraphy of pelvic lymph nodes with Indium 111-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-1955.
9. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
10. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointer J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH: Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer 1996;78:809-818.
11. Sanford E, Grzonka R, Heal A, Helal M, Persky L, Tyson I: Prostate cancer imaging with a new monoclonal antibody: A preliminary report. Ann Surg Oncol 1994;1:400-404.
12. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93:749-753.
13. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1996;62:552-558.
14. Sobin LH, Wittekind CH (eds): "TNM Classification of Malignant Tumours," 5th ed. New York: Wiley-Liss, 1997:170-173.
15. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren RJ, Murphy GP: The effects of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995;59:246-250.
16. Tillyer CR, Konings M, Gobin PT, Iqbal J: Disagreement between the Roche Cobas Core and Hybritech Tandem-E PSA assays when measuring free, complexed and total serum prostate specific antigen. Ann Clin Biochem 1994;31:501-505.
17. Metz C: Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-298.
18. Zweig M, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
19. Pfaffenberger RC, Paterson JH: "Statistical Methods for Business and Economics," Richard Irwin, Inc., 1977.
20. Nelp WB: Anti-prostate antibody (ProstaScint®) imaging preand post-operatively. Eighth Annual Symposium, Northwest Hospital, June 13-14, 1997:169-170.
21. Chengazi VU, Feneley MR, Ellison D, Stalteri M, Granowski A, Granowski M, Nimmon CC, Mather SJ, Kirby RS, Britton KF: Imaging prostate cancer with technetium-99m-7E11.C5.3 (CYT-351). J Nucl Med 1997;38:675-682.
22. Gervasi LA, Muta J, Easley JD, Wilbanks JH, Seale-Hawkins C, Calton CE Jr, Scardino PT: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-336.
23. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-1830.
24. Golimbu M, Morales P, Al-Askari S, Shulman Y: CAT scanning in staging of prostate cancer. Urology 1981;18:305-308.
25. Hricak H: Noninvasive imaging for staging of prostate cancer: Magnetic resonance imaging, computed tomography and ultrasound. NCI Manager 1988;7:31-35.